PT1257275E - Utilizacao de um antagonista dos receptores de canabinoides centrais para a preparacao de medicamentos uteis para facilitar a paragem do consumo de tabaco - Google Patents

Utilizacao de um antagonista dos receptores de canabinoides centrais para a preparacao de medicamentos uteis para facilitar a paragem do consumo de tabaco

Info

Publication number
PT1257275E
PT1257275E PT01907722T PT01907722T PT1257275E PT 1257275 E PT1257275 E PT 1257275E PT 01907722 T PT01907722 T PT 01907722T PT 01907722 T PT01907722 T PT 01907722T PT 1257275 E PT1257275 E PT 1257275E
Authority
PT
Portugal
Prior art keywords
antagonist
facilitate
stop
preparation
central
Prior art date
Application number
PT01907722T
Other languages
English (en)
Inventor
Jean Charles Blanchard
Francois Menard
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PT1257275E publication Critical patent/PT1257275E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT01907722T 2000-02-09 2001-02-07 Utilizacao de um antagonista dos receptores de canabinoides centrais para a preparacao de medicamentos uteis para facilitar a paragem do consumo de tabaco PT1257275E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (1)

Publication Number Publication Date
PT1257275E true PT1257275E (pt) 2005-07-29

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01907722T PT1257275E (pt) 2000-02-09 2001-02-07 Utilizacao de um antagonista dos receptores de canabinoides centrais para a preparacao de medicamentos uteis para facilitar a paragem do consumo de tabaco

Country Status (33)

Country Link
US (2) US6930122B2 (pt)
EP (1) EP1257275B1 (pt)
JP (2) JP2003522145A (pt)
CN (1) CN1250220C (pt)
AR (1) AR028505A1 (pt)
AT (1) ATE292467T1 (pt)
AU (1) AU781827B2 (pt)
BG (2) BG110386A (pt)
BR (1) BR0108126A (pt)
CA (1) CA2397262C (pt)
CZ (1) CZ296685B6 (pt)
DE (1) DE60109903T2 (pt)
DK (1) DK1257275T3 (pt)
EE (1) EE04836B1 (pt)
ES (1) ES2240416T3 (pt)
FR (1) FR2804604B1 (pt)
HK (1) HK1051140A1 (pt)
HU (1) HU225328B1 (pt)
IL (1) IL150710A0 (pt)
IS (1) IS6450A (pt)
MX (1) MXPA02007766A (pt)
NO (1) NO324521B1 (pt)
NZ (1) NZ519924A (pt)
PL (1) PL201685B1 (pt)
PT (1) PT1257275E (pt)
RS (1) RS50404B (pt)
RU (1) RU2257207C2 (pt)
SI (1) SI1257275T1 (pt)
SK (1) SK284952B6 (pt)
TW (1) TWI243677B (pt)
UA (1) UA72783C2 (pt)
WO (1) WO2001058450A2 (pt)
ZA (1) ZA200205317B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
AU2002323126A1 (en) 2001-08-13 2003-03-03 Honeywell International Inc. Systems for wafer level burn-in of electronic devices
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
CA2481313A1 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
EP1546115A4 (en) 2002-09-27 2010-08-04 Merck Sharp & Dohme SUBSTITUTED PYRIMIDINES
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2004058145A2 (en) 2002-12-19 2004-07-15 Merck & Co., Inc. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
JP2007501279A (ja) * 2003-05-20 2007-01-25 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデイション カンナビノイド誘導体、その製造方法、および使用
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
JP2007510647A (ja) * 2003-10-30 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体調節剤としてのアラルキルアミン類
NZ580387A (en) 2004-07-12 2011-06-30 Cadila Healthcare Ltd Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
CA2637565A1 (en) * 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (fr) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
EA026213B1 (ru) * 2006-10-20 2017-03-31 Солвей Фармасьютикалс Б.В. Термостабильная твердая фармацевтическая композиция, содержащая наномицеллы, и способ ее получения
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
BRPI0814806A2 (pt) * 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
WO2001058450A2 (fr) 2001-08-16
CZ296685B6 (cs) 2006-05-17
WO2001058450A3 (fr) 2002-04-25
US20050187253A1 (en) 2005-08-25
AU781827B2 (en) 2005-06-16
ZA200205317B (en) 2003-09-04
BG65856B1 (bg) 2010-03-31
CN1406128A (zh) 2003-03-26
SK11292002A3 (sk) 2003-02-04
EE200200439A (et) 2003-12-15
TWI243677B (en) 2005-11-21
BG110386A (en) 2009-09-30
EE04836B1 (et) 2007-06-15
RU2002118309A (ru) 2004-02-20
MXPA02007766A (es) 2002-10-11
SI1257275T1 (en) 2005-10-31
YU59002A (sh) 2005-07-19
BG106946A (bg) 2003-05-30
DE60109903D1 (de) 2005-05-12
IS6450A (is) 2002-06-28
IL150710A0 (en) 2003-02-12
NO20023765D0 (no) 2002-08-08
BR0108126A (pt) 2003-01-28
UA72783C2 (en) 2005-04-15
SK284952B6 (sk) 2006-03-02
HU225328B1 (en) 2006-09-28
NZ519924A (en) 2005-01-28
HK1051140A1 (en) 2003-07-25
JP2003522145A (ja) 2003-07-22
RS50404B (sr) 2009-12-31
EP1257275A2 (fr) 2002-11-20
CA2397262A1 (en) 2001-08-16
CA2397262C (en) 2007-09-11
NO20023765L (no) 2002-10-09
CN1250220C (zh) 2006-04-12
FR2804604A1 (fr) 2001-08-10
HUP0300237A3 (en) 2003-09-29
HUP0300237A2 (hu) 2003-07-28
NO324521B1 (no) 2007-11-12
US6930122B2 (en) 2005-08-16
US20030087933A1 (en) 2003-05-08
JP2010018622A (ja) 2010-01-28
PL358221A1 (en) 2004-08-09
ATE292467T1 (de) 2005-04-15
DK1257275T3 (da) 2005-08-08
PL201685B1 (pl) 2009-04-30
EP1257275B1 (fr) 2005-04-06
DE60109903T2 (de) 2006-02-09
RU2257207C2 (ru) 2005-07-27
AU3562001A (en) 2001-08-20
FR2804604B1 (fr) 2005-05-27
ES2240416T3 (es) 2005-10-16
CZ20022698A3 (cs) 2002-11-13
AR028505A1 (es) 2003-05-14

Similar Documents

Publication Publication Date Title
PT1257275E (pt) Utilizacao de um antagonista dos receptores de canabinoides centrais para a preparacao de medicamentos uteis para facilitar a paragem do consumo de tabaco
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
ATE480539T1 (de) Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
RS50209B (sr) Derivati pirazolokarboksilne kiseline, njihova priprema, farmaceutske kompozicije sa sadržajem istih
NZ501112A (en) Substituted pyrazoles as p38 kinase inhibitors
EA200300999A1 (ru) Хронотерапевтические дозированные формы
RS50876B (sr) Upotreba flibanserina u lečenju seksualnih poremećaja
JP2003522145A5 (pt)
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
NO20023728D0 (no) Manipuleringsresistente, orale opioidagonistformuleringer
TNSN06272A1 (en) Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
DE50102752D1 (de) Fungizide wirkstoffkombinationen
WO2004112771A8 (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
TW200616950A (en) Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (yc-1) as anti-platelet agents
BR0011174A (pt) Composições, compostos, compostos isolados e métodos para controlar pestes
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
EA200501818A1 (ru) Индазолы, обладающие анальгетической активностью
FR2861992B1 (fr) Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
AR033261A1 (es) Antagonistas de nmda para el tratamiento de enfermedades adictivas
WO2005046656A3 (en) Use of 5 - chloro-1- (2, 6 - dichloro - 4 - trifluoromethylphenyl) - 4 - (4, 5 - dicyano - 1h - imidazol - 2yl) -3 - methyl - 1h - pyrazole in systemic control of acarid infestation on animals
TH49075A (th) อนุพันธ์ไพราโซลคาร์บอกซิลิคแอซิด การเตรียมอนุพันธ์เหล่านี้และ องค์ประกอบทางเภสัชกรรมที่มีอนุพันธ์เหล่านี้
SI1611144T1 (sl) Derivati 2-(8,9-diokso-2,6-diazabiciklo(5.2.0)non-1(7)-en-2-il)alkil fosfonske kisline in njihova uporaba kot antagonisti N-metil-D-aspartat(NMDA) receptorja